TCR-based Therapies for Solid Tumors Summit
Evvnt Promotion / evvnt
Archivo
03.04.2023 - 05.04.2023 Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, Massachusetts, USA
Time: 09:00 to 16:30
Temas de la conferencia
The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
La Sociedad Científica
Hanson Wade
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/1444012-3?pid=4832
Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, and more
Brochure: https://go.evvnt.com/1444012-3?pid=4832
Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, and more
Información e inscripción:
https://go.evvnt.com/1444012-2?pid=4832
Ms. Ellie Saunders
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
